Mostrar el registro sencillo del ítem

Artículo

dc.creatorGarrido Cumbrera, Marcoes
dc.creatorMarzo Ortega, Helenaes
dc.creatorChristen, Lauraes
dc.creatorPlazuelo Ramos, Pedroes
dc.creatorWebb, Dalees
dc.creatorJacklin, Clarees
dc.creatorIrwin, Shanteles
dc.creatorGrange, Laurentes
dc.creatorMakri, Souzies
dc.creatorFrazao Mateus, Elsaes
dc.creatorMingolla, Serenaes
dc.creatorAntonopoulou, Katyes
dc.creatorSanz Gómez, Sergioes
dc.creatorCorrea Fernández, Josées
dc.creatorCarmona, Loretoes
dc.creatorNavarro Compán, Victoriaes
dc.date.accessioned2022-10-11T08:07:17Z
dc.date.available2022-10-11T08:07:17Z
dc.date.issued2021
dc.identifier.citationGarrido Cumbrera, M., Marzo Ortega, H., Christen, L., Plazuelo Ramos, P., Webb, D., Jacklin, C.,...,Navarro Compán, V. (2021). Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). RMD OPEN, 7 (1). https://doi.org/10.1136/rmdopen-2020-001546.
dc.identifier.issn2056-5933es
dc.identifier.urihttps://hdl.handle.net/11441/137792
dc.description.abstractAim To assess the impact of the COVID-19 pandemic on patients with rheumatic and musculoskeletal diseases (RMDs). Methods REUMAVID is a cross-sectional study using an online survey developed by an international multidisciplinary patient-led collaboration across seven European countries targeting unselected patients with RMDs. Healthcare access, daily activities, disease activity and function, well-being (WHO Five Well-Being Index (WHO-5)), health status, anxiety/depression (Hospital Anxiety and Depression Scale (HADS)) and access to information were evaluated. Data were collected in April–July 2020 (first phase). Results Data from the first phase included 1800 patients with 15 different RMDs (37.2% axial spondyloarthritis, 29.2% rheumatoid arthritis, 17.2% osteoarthritis and others). Mean age was 53, 80% female and 49% had undertaken university studies. During the beginning of the pandemic, 58.4% had their rheumatology appointment cancelled and 45.6% reported not having received any information relating to the possible impact of SARS-CoV-2 infection in their RMDs, with the main source being patient organisations (27.6%). Regarding habits, 24.6% increased smoking, 18.2% raised their alcohol consumption, and 45.6% were unable to continue exercising. Self-reported disease activity was high (5.3±2.7) and 75.6% reported elevated pain. Half the patients (49.0%) reported poor well-being (WHO-5) and 46.6% that their health had changed for the worse during lockdown. According to HADS, 57.3% were at risk of anxiety and 45.9% of depression. Conclusion Throughout the first wave of the COVID-19 pandemic, patients with RMDs have experienced disruption in access to healthcare services, poor lifestyle habits and negative effects on their overall health, well-being and mental health. Furthermore, information on COVID-19 has not reached patients appropriately.es
dc.formatapplication/pdfes
dc.format.extent10 p.es
dc.language.isoenges
dc.publisherBMJ PUBLISHING GROUPes
dc.relation.ispartofRMD OPEN, 7 (1).
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleAssessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1)es
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Geografía Física y Análisis Geográfico Regionales
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Psiquiatríaes
dc.relation.publisherversionhttp://dx.doi.org/10.1136/rmdopen-2020-001546es
dc.identifier.doi10.1136/rmdopen-2020-001546es
dc.journaltitleRMD OPENes
dc.publication.volumen7es
dc.publication.issue1es

FicherosTamañoFormatoVerDescripción
e001546.full.pdf740.7KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional